A first Phase II study of IONIS-FB-LRx in patients with dry age-related macular degeneration (AMD).
Phase of Trial: Phase II
Latest Information Update: 17 Aug 2017
At a glance
- Drugs IONIS-FB-LRX (Primary)
- Indications Dry age-related macular degeneration
- Focus Therapeutic Use
- 17 Aug 2017 New trial record
- 11 Aug 2017 According to an Ionis Pharmaceuticals media release, company plans to initiate this study later this year.